Pharma & Healthcare

Global Acute Vulvovaginal Candidiasis Treatment Market Research Report 2025

The global market for Acute Vulvovaginal Candidiasis Treatment was valued at US$ 1117 million in the year 2024 and is projected to reach a revised size of US$ 1578 million by 2031, growing at a CAGR of 5.1% during the forecast period.
Acute vulvovaginal candidiasis is a fungal/yeast infection, which is caused by some species of Candida, especially Candida albicans. Increasing cases of vulvovaginal candidiasis can be attributed to ageing, overuse of antibiotics, diabetes, etc. Doctors are involved in prescribing medicines on the basis of their efficiency in controlling acute vulvovaginal candidiasis among the patients.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Acute Vulvovaginal Candidiasis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Vulvovaginal Candidiasis Treatment.
The Acute Vulvovaginal Candidiasis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Acute Vulvovaginal Candidiasis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Vulvovaginal Candidiasis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Mycovia Pharmaceuticals, Inc
Scynexis, Inc
Basilea Pharmaceutica Ltd
Astellas Pharma Inc
Grupo Ferrer Internacional, S.A
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc
Cidara Therapeutics, Inc
Amplyx Pharmaceuticals Inc
Pfizer, Inc.
Bristol-Myers Squibb Company
Cadila Pharmaceuticals
Bayer AG.
Lupin
Phathom Pharmaceutical, Inc
Novartis AG
Mylan N.V.
Sandoz International GmbH
Accord Healthcare Ltd
Amneal Pharmaceuticals LLC
Segment by Type
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Vulvovaginal Candidiasis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Clotrimazole
1.2.3 Nystatin
1.2.4 Fluconazole
1.2.5 Ketoconazole
1.2.6 Terbinafine
1.2.7 Terconazole
1.2.8 Others
1.3 Market by Application
1.3.1 Global Acute Vulvovaginal Candidiasis Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Perspective (2020-2031)
2.2 Global Acute Vulvovaginal Candidiasis Treatment Growth Trends by Region
2.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Region (2020-2025)
2.2.3 Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Region (2026-2031)
2.3 Acute Vulvovaginal Candidiasis Treatment Market Dynamics
2.3.1 Acute Vulvovaginal Candidiasis Treatment Industry Trends
2.3.2 Acute Vulvovaginal Candidiasis Treatment Market Drivers
2.3.3 Acute Vulvovaginal Candidiasis Treatment Market Challenges
2.3.4 Acute Vulvovaginal Candidiasis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue
3.1.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue (2020-2025)
3.1.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Acute Vulvovaginal Candidiasis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Acute Vulvovaginal Candidiasis Treatment Revenue
3.4 Global Acute Vulvovaginal Candidiasis Treatment Market Concentration Ratio
3.4.1 Global Acute Vulvovaginal Candidiasis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Vulvovaginal Candidiasis Treatment Revenue in 2024
3.5 Global Key Players of Acute Vulvovaginal Candidiasis Treatment Head office and Area Served
3.6 Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Product and Application
3.7 Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Type
4.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Type (2020-2025)
4.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2026-2031)
5 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Application
5.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Application (2020-2025)
5.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)
6.2 North America Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025)
6.4 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)
7.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025)
7.4 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)
8.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)
9.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025)
9.4 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)
10.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mycovia Pharmaceuticals, Inc
11.1.1 Mycovia Pharmaceuticals, Inc Company Details
11.1.2 Mycovia Pharmaceuticals, Inc Business Overview
11.1.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
11.1.4 Mycovia Pharmaceuticals, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.1.5 Mycovia Pharmaceuticals, Inc Recent Development
11.2 Scynexis, Inc
11.2.1 Scynexis, Inc Company Details
11.2.2 Scynexis, Inc Business Overview
11.2.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
11.2.4 Scynexis, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.2.5 Scynexis, Inc Recent Development
11.3 Basilea Pharmaceutica Ltd
11.3.1 Basilea Pharmaceutica Ltd Company Details
11.3.2 Basilea Pharmaceutica Ltd Business Overview
11.3.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Introduction
11.3.4 Basilea Pharmaceutica Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.3.5 Basilea Pharmaceutica Ltd Recent Development
11.4 Astellas Pharma Inc
11.4.1 Astellas Pharma Inc Company Details
11.4.2 Astellas Pharma Inc Business Overview
11.4.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Introduction
11.4.4 Astellas Pharma Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.4.5 Astellas Pharma Inc Recent Development
11.5 Grupo Ferrer Internacional, S.A
11.5.1 Grupo Ferrer Internacional, S.A Company Details
11.5.2 Grupo Ferrer Internacional, S.A Business Overview
11.5.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Introduction
11.5.4 Grupo Ferrer Internacional, S.A Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.5.5 Grupo Ferrer Internacional, S.A Recent Development
11.6 Pacgen Life Science Corporation
11.6.1 Pacgen Life Science Corporation Company Details
11.6.2 Pacgen Life Science Corporation Business Overview
11.6.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Introduction
11.6.4 Pacgen Life Science Corporation Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.6.5 Pacgen Life Science Corporation Recent Development
11.7 NovaDigm Therapeutics, Inc
11.7.1 NovaDigm Therapeutics, Inc Company Details
11.7.2 NovaDigm Therapeutics, Inc Business Overview
11.7.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
11.7.4 NovaDigm Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.7.5 NovaDigm Therapeutics, Inc Recent Development
11.8 Cidara Therapeutics, Inc
11.8.1 Cidara Therapeutics, Inc Company Details
11.8.2 Cidara Therapeutics, Inc Business Overview
11.8.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
11.8.4 Cidara Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.8.5 Cidara Therapeutics, Inc Recent Development
11.9 Amplyx Pharmaceuticals Inc
11.9.1 Amplyx Pharmaceuticals Inc Company Details
11.9.2 Amplyx Pharmaceuticals Inc Business Overview
11.9.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Introduction
11.9.4 Amplyx Pharmaceuticals Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.9.5 Amplyx Pharmaceuticals Inc Recent Development
11.10 Pfizer, Inc.
11.10.1 Pfizer, Inc. Company Details
11.10.2 Pfizer, Inc. Business Overview
11.10.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Introduction
11.10.4 Pfizer, Inc. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.10.5 Pfizer, Inc. Recent Development
11.11 Bristol-Myers Squibb Company
11.11.1 Bristol-Myers Squibb Company Company Details
11.11.2 Bristol-Myers Squibb Company Business Overview
11.11.3 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Introduction
11.11.4 Bristol-Myers Squibb Company Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.11.5 Bristol-Myers Squibb Company Recent Development
11.12 Cadila Pharmaceuticals
11.12.1 Cadila Pharmaceuticals Company Details
11.12.2 Cadila Pharmaceuticals Business Overview
11.12.3 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Introduction
11.12.4 Cadila Pharmaceuticals Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.12.5 Cadila Pharmaceuticals Recent Development
11.13 Bayer AG.
11.13.1 Bayer AG. Company Details
11.13.2 Bayer AG. Business Overview
11.13.3 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Introduction
11.13.4 Bayer AG. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.13.5 Bayer AG. Recent Development
11.14 Lupin
11.14.1 Lupin Company Details
11.14.2 Lupin Business Overview
11.14.3 Lupin Acute Vulvovaginal Candidiasis Treatment Introduction
11.14.4 Lupin Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.14.5 Lupin Recent Development
11.15 Phathom Pharmaceutical, Inc
11.15.1 Phathom Pharmaceutical, Inc Company Details
11.15.2 Phathom Pharmaceutical, Inc Business Overview
11.15.3 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
11.15.4 Phathom Pharmaceutical, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.15.5 Phathom Pharmaceutical, Inc Recent Development
11.16 Novartis AG
11.16.1 Novartis AG Company Details
11.16.2 Novartis AG Business Overview
11.16.3 Novartis AG Acute Vulvovaginal Candidiasis Treatment Introduction
11.16.4 Novartis AG Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.16.5 Novartis AG Recent Development
11.17 Mylan N.V.
11.17.1 Mylan N.V. Company Details
11.17.2 Mylan N.V. Business Overview
11.17.3 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Introduction
11.17.4 Mylan N.V. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.17.5 Mylan N.V. Recent Development
11.18 Sandoz International GmbH
11.18.1 Sandoz International GmbH Company Details
11.18.2 Sandoz International GmbH Business Overview
11.18.3 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Introduction
11.18.4 Sandoz International GmbH Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.18.5 Sandoz International GmbH Recent Development
11.19 Accord Healthcare Ltd
11.19.1 Accord Healthcare Ltd Company Details
11.19.2 Accord Healthcare Ltd Business Overview
11.19.3 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Introduction
11.19.4 Accord Healthcare Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.19.5 Accord Healthcare Ltd Recent Development
11.20 Amneal Pharmaceuticals LLC
11.20.1 Amneal Pharmaceuticals LLC Company Details
11.20.2 Amneal Pharmaceuticals LLC Business Overview
11.20.3 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Introduction
11.20.4 Amneal Pharmaceuticals LLC Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
11.20.5 Amneal Pharmaceuticals LLC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Clotrimazole
Table 3. Key Players of Nystatin
Table 4. Key Players of Fluconazole
Table 5. Key Players of Ketoconazole
Table 6. Key Players of Terbinafine
Table 7. Key Players of Terconazole
Table 8. Key Players of Others
Table 9. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2020-2025)
Table 13. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2026-2031)
Table 15. Acute Vulvovaginal Candidiasis Treatment Market Trends
Table 16. Acute Vulvovaginal Candidiasis Treatment Market Drivers
Table 17. Acute Vulvovaginal Candidiasis Treatment Market Challenges
Table 18. Acute Vulvovaginal Candidiasis Treatment Market Restraints
Table 19. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Players (2020-2025)
Table 21. Global Top Acute Vulvovaginal Candidiasis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Vulvovaginal Candidiasis Treatment as of 2024)
Table 22. Ranking of Global Top Acute Vulvovaginal Candidiasis Treatment Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Acute Vulvovaginal Candidiasis Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Headquarters and Area Served
Table 25. Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Product and Application
Table 26. Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2020-2025)
Table 30. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2026-2031)
Table 32. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2020-2025)
Table 34. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2026-2031)
Table 36. North America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 51. Mycovia Pharmaceuticals, Inc Company Details
Table 52. Mycovia Pharmaceuticals, Inc Business Overview
Table 53. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product
Table 54. Mycovia Pharmaceuticals, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 55. Mycovia Pharmaceuticals, Inc Recent Development
Table 56. Scynexis, Inc Company Details
Table 57. Scynexis, Inc Business Overview
Table 58. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product
Table 59. Scynexis, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 60. Scynexis, Inc Recent Development
Table 61. Basilea Pharmaceutica Ltd Company Details
Table 62. Basilea Pharmaceutica Ltd Business Overview
Table 63. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product
Table 64. Basilea Pharmaceutica Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 65. Basilea Pharmaceutica Ltd Recent Development
Table 66. Astellas Pharma Inc Company Details
Table 67. Astellas Pharma Inc Business Overview
Table 68. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product
Table 69. Astellas Pharma Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 70. Astellas Pharma Inc Recent Development
Table 71. Grupo Ferrer Internacional, S.A Company Details
Table 72. Grupo Ferrer Internacional, S.A Business Overview
Table 73. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product
Table 74. Grupo Ferrer Internacional, S.A Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 75. Grupo Ferrer Internacional, S.A Recent Development
Table 76. Pacgen Life Science Corporation Company Details
Table 77. Pacgen Life Science Corporation Business Overview
Table 78. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product
Table 79. Pacgen Life Science Corporation Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 80. Pacgen Life Science Corporation Recent Development
Table 81. NovaDigm Therapeutics, Inc Company Details
Table 82. NovaDigm Therapeutics, Inc Business Overview
Table 83. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product
Table 84. NovaDigm Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 85. NovaDigm Therapeutics, Inc Recent Development
Table 86. Cidara Therapeutics, Inc Company Details
Table 87. Cidara Therapeutics, Inc Business Overview
Table 88. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product
Table 89. Cidara Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 90. Cidara Therapeutics, Inc Recent Development
Table 91. Amplyx Pharmaceuticals Inc Company Details
Table 92. Amplyx Pharmaceuticals Inc Business Overview
Table 93. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product
Table 94. Amplyx Pharmaceuticals Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 95. Amplyx Pharmaceuticals Inc Recent Development
Table 96. Pfizer, Inc. Company Details
Table 97. Pfizer, Inc. Business Overview
Table 98. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product
Table 99. Pfizer, Inc. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 100. Pfizer, Inc. Recent Development
Table 101. Bristol-Myers Squibb Company Company Details
Table 102. Bristol-Myers Squibb Company Business Overview
Table 103. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product
Table 104. Bristol-Myers Squibb Company Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 105. Bristol-Myers Squibb Company Recent Development
Table 106. Cadila Pharmaceuticals Company Details
Table 107. Cadila Pharmaceuticals Business Overview
Table 108. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product
Table 109. Cadila Pharmaceuticals Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 110. Cadila Pharmaceuticals Recent Development
Table 111. Bayer AG. Company Details
Table 112. Bayer AG. Business Overview
Table 113. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product
Table 114. Bayer AG. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 115. Bayer AG. Recent Development
Table 116. Lupin Company Details
Table 117. Lupin Business Overview
Table 118. Lupin Acute Vulvovaginal Candidiasis Treatment Product
Table 119. Lupin Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 120. Lupin Recent Development
Table 121. Phathom Pharmaceutical, Inc Company Details
Table 122. Phathom Pharmaceutical, Inc Business Overview
Table 123. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product
Table 124. Phathom Pharmaceutical, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 125. Phathom Pharmaceutical, Inc Recent Development
Table 126. Novartis AG Company Details
Table 127. Novartis AG Business Overview
Table 128. Novartis AG Acute Vulvovaginal Candidiasis Treatment Product
Table 129. Novartis AG Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 130. Novartis AG Recent Development
Table 131. Mylan N.V. Company Details
Table 132. Mylan N.V. Business Overview
Table 133. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product
Table 134. Mylan N.V. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 135. Mylan N.V. Recent Development
Table 136. Sandoz International GmbH Company Details
Table 137. Sandoz International GmbH Business Overview
Table 138. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product
Table 139. Sandoz International GmbH Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 140. Sandoz International GmbH Recent Development
Table 141. Accord Healthcare Ltd Company Details
Table 142. Accord Healthcare Ltd Business Overview
Table 143. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product
Table 144. Accord Healthcare Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 145. Accord Healthcare Ltd Recent Development
Table 146. Amneal Pharmaceuticals LLC Company Details
Table 147. Amneal Pharmaceuticals LLC Business Overview
Table 148. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product
Table 149. Amneal Pharmaceuticals LLC Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)
Table 150. Amneal Pharmaceuticals LLC Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
Table 154. Authors List of This Report


List of Figures
Figure 1. Acute Vulvovaginal Candidiasis Treatment Picture
Figure 2. Global Acute Vulvovaginal Candidiasis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Type: 2024 VS 2031
Figure 4. Clotrimazole Features
Figure 5. Nystatin Features
Figure 6. Fluconazole Features
Figure 7. Ketoconazole Features
Figure 8. Terbinafine Features
Figure 9. Terconazole Features
Figure 10. Others Features
Figure 11. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 12. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Application: 2024 VS 2031
Figure 13. Hospital Pharmacies Case Studies
Figure 14. Retail Pharmacies Case Studies
Figure 15. Online Pharmacies Case Studies
Figure 16. Acute Vulvovaginal Candidiasis Treatment Report Years Considered
Figure 17. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Acute Vulvovaginal Candidiasis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region: 2024 VS 2031
Figure 20. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Players in 2024
Figure 21. Global Top Acute Vulvovaginal Candidiasis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Vulvovaginal Candidiasis Treatment as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Acute Vulvovaginal Candidiasis Treatment Revenue in 2024
Figure 23. North America Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2020-2031)
Figure 25. United States Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2020-2031)
Figure 29. Germany Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2020-2031)
Figure 37. China Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Japan Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. South Korea Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. India Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Australia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2020-2031)
Figure 45. Mexico Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Brazil Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2020-2031)
Figure 49. Turkey Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. UAE Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Mycovia Pharmaceuticals, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 53. Scynexis, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 54. Basilea Pharmaceutica Ltd Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 55. Astellas Pharma Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 56. Grupo Ferrer Internacional, S.A Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 57. Pacgen Life Science Corporation Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 58. NovaDigm Therapeutics, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 59. Cidara Therapeutics, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 60. Amplyx Pharmaceuticals Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 61. Pfizer, Inc. Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 62. Bristol-Myers Squibb Company Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 63. Cadila Pharmaceuticals Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 64. Bayer AG. Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 65. Lupin Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 66. Phathom Pharmaceutical, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 67. Novartis AG Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 68. Mylan N.V. Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 69. Sandoz International GmbH Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 70. Accord Healthcare Ltd Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 71. Amneal Pharmaceuticals LLC Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies